LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its proprietary drug candidate INNO-206 dramatically inhibited tumor growth in an experimental animal model of small cell lung cancer (SCLC). The results of the trial have been released in electronic form and accepted for publication in the peer-reviewed journal Investigational New Drugs.
